CTRI/2024/01/062147招募中3 期
A Multicentric, Randomized, Double Blind, Double Dummy, Prospective, Parallel Group, Comparative, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of FDC of Pregabalin plus Methylcobalamin plus Duloxetine (Delayed Release) Capsules Versus FDC of Pregabalin plus Methylcobalamin plus Nortriptyline Tablets in Subjects with Diabetic Peripheral Neuropathic Pain Coexisting with Vitamin B12 Deficiency. - NI
Ravenbhel Healthcare Pvt. Ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Male or Female subjects between 18 to 75 years of age (both inclusive).
- •2.Subjects with a diagnosis of type 2 diabetes mellitus with glycosylated hemoglobin (HbA1c) =12% and having pain associated with diabetic peripheral neuropathy= 3 months.
- •3.Subjects with pain intensity = 4 on 0-10 points of visual analog scale (VAS).
- •4.Subjects with decreased vitamin B12 levels ( < 200 pg/mL) at screening visit.
- •5.Subjects who are willing to sign written informed consent for participation in the study.
- •6.Subjects willing to adhere to all protocol procedures.
排除标准
- •1.Subjects with hypersensitivity to either of the study medications or any of the ingredients of the formulation.
- •2.Patients with prior therapy with Pregabalin or Duloxetine or Nortriptyline and having any other neurologic disorders unrelated to diabetic peripheral neuropathic pain were excluded.
- •3.Patients with clinically significant impaired hepatic function. [SGOT & SGPT more than 3X the UNL and/or Total bilirubin more than 1.5X the UNL].
- •4.Subject with abnormal eGFR ( <60 mL/min/1.73 m2).
- •5.Subjects with Serum creatinine more than 1.5X the ULN.
- •6.Patients with any abnormality on 12 lead ECG readings and the results are deemed clinically significant by the investigator.
- •7.Subjects with a history of HIV, Hepatitis B & C.
- •8.Female patients who are pregnant or lactating or planning to become pregnant during the study period.
- •9.Females who are not ready to use acceptable contraceptive methods during the course of study.
- •10.Subjects who, in the opinion of the investigator, have a history of clinically significant cardiovascular disease (e.g. MI), subjects who are on pacemakers, central nervous system disorders (e.g. seizure, bipolar disorder, generalized anxiety disorder, untreated depression, psychosis or post-traumatic stress disorder), suicidal behavior, glaucoma, angioedema, urinary retention, thyroid disorder, uncontrolled hypertension, bleeding disorders.
- •11.Subjects with history of suicidal thoughts and behavior.
- •12.Subjects with serum sodium level <130 mmol/L at screening.
- •13.Subjects with uncontrolled hypertension with sitting SBP = 160 mmHg and/or DBP = 100 mmHg at screening.
- •14.Patient treated with topical or systemic pain medications within past 2 weeks prior to baseline.
- •15.Subjects with known alcohol or other substance abuse.
- •16.Subjects with a medical history of Oncological Conditions.
- •17.Concurrent participation in another clinical trial or any investigational therapy within 90 days prior to signing informed consent.
- •18.Currently taking prohibited medications(s) listed and inability/unwillingness to discontinue them for the entire study period.
- •19.Participant has a clinically significant disorder that, in the opinion of the investigator, would result in the participant’s inability to understand and comply with the requirements of the study.
研究者
相似试验
尚未招募
3 期
A Multicentric Randomized Double Blind Double Dummy Parallel Group Comparative Phase III Clinical Study to Evaluate the Efficacy Safety and Tolerability in subjects with Uncontrolled Essential Hypertension with stable Coronary Artery Disease (CAD).CTRI/2022/11/047055Ajanta Pharma Limited
尚未招募
3 期
A clinical study to assess the efficacy and safety of Pregabalin, Duloxetine and Mecobalamin Capsules in neuropathic pain patients.CTRI/2024/03/063691Synokem Pharmaceuticals Ltd
尚未招募
3 期
A clinical study to see the effect and safety of Fixed Dose Combination of Silodosin and Solifenacin Capsules in Comparison to Silodosin Capsules in Male Patients Having Benign Prostatic Hyperplasia (BPH)/ Lower Urinary Tract Symptoms (LUTS) with Over Active Bladder (OAB)CTRI/2020/07/026419Sun Pharma Laboratories Limited
已完成
3 期
A clinical study to assess the efficacy and safety of combination of Azilsartan and Amlodipine Tablets in patients with hypertension.CTRI/2022/02/040081Inventia Healthcare Ltd309
已完成
3 期
A clinical study to assess the efficacy and safety of Imeglimin Tablets in patients with diabetes.CTRI/2022/02/040348Exemed Pharmaceuticals216